Department of Pharmacology, Penn State College of Medicine, 1214 Research Boulevard, Hummelstown, PA 17036, USA.
Gut Pathog. 2011 Oct 20;3(1):16. doi: 10.1186/1757-4749-3-16.
Probiotics have beneficial effects in rodent models of Clostridium difficile (C. diffiicle)-induced colitis. The spore forming probiotic strain Bacillus Coagulans GBI-30, 6086 (BC30) has demonstrated anti-inflammatory and immune-modulating effects in vitro. Our goal was to determine if BC30 improved C. difficile-induced colitis in mice. Starting on study day 0, female C57BL/6 mice were dosed by oro-gastric gavage for 15 days with vehicle (saline) or BC30 (2 × 109 CFU per day). Mice in the C. difficile groups received an antibiotic mixture (study days 5 to 8 in the drinking water), and clindamycin (10 mg/kg, i.p., on study day 10). The C. difficile strain VPI 10463 was given by gavage at 104 CFU to induce colitis on day 11. On day 16, stools and colons were collected for further analyses.
All mice treated with BC30 survived on study day 13, while two mice treated with vehicle did not survive. On day 12, a significant difference (p = 0.0002) in the percentage of mice with normal stools (66.7%) was found in the BC30/C. difficile group, as compared to the vehicle/C. diffcile group (13.0%). On study day 16, 23.8% of mice treated with BC30 had normal stools, while this value was 0% with vehicle treatment (p value = 0.0187). On this day, the stool consistency score for the BC30/C. difficile group (1.1 ± 0.2) was significantly lower (p < 0.05) than for the vehicle/C. difficile cohort (1.9 ± 0.2). BC30 modestly attenuated the colonic pathology (crypt damage, edema, leukocyte influx) that was present following C. difficile infection. Colonic MIP-2 chemokine contents (pg/2 cm colon) were: 10.2 ± 0.5 (vehicle/no C. difficile), 24.6 ± 9.5 (vehicle/C. difficile) and 16.3 ± 4.3 (BC30/C. difficle).
The probiotic BC30 improved some parameters of C. difficile-induced colitis in mice. BC30 prolonged the survival of C. diffiicle infected mice. Particularly, this probiotic improved the stool consistency of mice, in this infectious colitis model.
益生菌对艰难梭菌（C. difficile）诱导的结肠炎的啮齿动物模型具有有益作用。形成孢子的益生菌菌株凝结芽孢杆菌 GBI-30,6086（BC30）已在体外显示出抗炎和免疫调节作用。我们的目标是确定 BC30 是否能改善小鼠中的艰难梭菌诱导的结肠炎。从研究日 0 开始，通过口咽灌胃，雌性 C57BL/6 小鼠连续 15 天接受载体（生理盐水）或 BC30（每天 2×109 CFU）治疗。艰难梭菌组的小鼠接受抗生素混合物（饮水 5 至 8 天）和克林霉素（10mg/kg，腹腔注射，第 10 天）治疗。在第 11 天，通过灌胃给予艰难梭菌菌株 VPI 10463，以 104 CFU 诱导结肠炎。在第 16 天，收集粪便和结肠进行进一步分析。
所有接受 BC30 治疗的小鼠在研究日 13 幸存，而接受载体治疗的两只小鼠未幸存。在第 12 天，BC30/艰难梭菌组中，粪便正常的小鼠百分比（66.7%）有显著差异（p=0.0002），而载体/艰难梭菌组为 13.0%。在研究日 16 天，23.8%接受 BC30 治疗的小鼠粪便正常，而接受载体治疗的小鼠粪便正常为 0%（p 值=0.0187）。在这一天，BC30/艰难梭菌组的粪便稠度评分（1.1±0.2）明显低于载体/艰难梭菌组（1.9±0.2）（p<0.05）。BC30 适度减轻了艰难梭菌感染后存在的结肠病理（隐窝损伤、水肿、白细胞浸润）。结肠 MIP-2 趋化因子含量（2cm 结肠 pg）分别为：载体/无艰难梭菌 10.2±0.5、载体/艰难梭菌 24.6±9.5 和 BC30/艰难梭菌 16.3±4.3。
益生菌 BC30 改善了小鼠中艰难梭菌诱导的结肠炎的一些参数。BC30 延长了艰难梭菌感染小鼠的存活时间。特别是，这种益生菌改善了感染性结肠炎模型中小鼠的粪便稠度。
